Skip to main content

View full-text article in PMC

. 2022 Sep 2;101(35):e30144. doi: 10.1097/MD.0000000000030144

Table 8.

McGill short-form questionnaire comparison between turmeric-boswellia formulation (TBF) and placebo group.

MPQ Score	TBF					Placebo
MPQ Score	Mean ± SD	Mean difference ± SD	95 % CL (LL–UL)	P ^*	SRM^†	Mean ± SD	Mean difference ± SD	95 % CL (LL–UL)	P ^*	SRM^†
MPQ sensory (scale 0–33)
Pretreatment	11.1 ± 6.08	10.9 ± 6.17	9.8–12	<.001	1.77	11.2 ± 5.8	−0.2 ± 1.08	−0.4 to 0	.0857	0.19
Posttreatment	0.2 ± 0.95	10.9 ± 6.17	9.8–12	<.001	1.77	11.4 ± 5.98	−0.2 ± 1.08	−0.4 to 0	.0857	0.19
MPQ affective (scale 0–12)
Pretreatment	3.1 ± 2.62	3 ± 2.61	2.5–3.5	<.001	1.15	3 ± 2.54	0 ± 1.32	−0.2 to 0.3	.3775	0
Posttreatment	0.1 ± 0.58	3 ± 2.61	2.5–3.5	<.001	1.15	3 ± 2.45	0 ± 1.32	−0.2 to 0.3	.3775	0
Total MPQ (scale 0–45)
Pretreatment	14.2 ± 5.83	13.9 ± 6.01	12.8–15	<.001	2.31	14.2 ± 5.37	−0.1 ± 1.98	−0.5 to 0.2	.1429	0.1
Posttreatment	0.3 ± 1.46	13.9 ± 6.01	12.8–15	<.001	2.31	14.4 ± 5.66	−0.1 ± 1.98	−0.5 to 0.2	.1429	0.1
VAS
Pretreatment	80.7 ± 12.46	78.6 ± 14.27	75.9–81.2	<.001	5.51	80.5 ± 12.06	−1 ± 9.86	−2.8 to 0.8	.0011	0.1
Posttreatment	2.1 ± 8.5	78.6 ± 14.27	75.9–81.2	<.001	5.51	81.5 ± 14.84	−1 ± 9.86	−2.8 to 0.8	.0011	0.1
PPI
Pretreatment	4.3 ± 0.69	4.1 ± 0.82	3.9–4.2	<.001	4.88	4.1 ± 0.76	−0.1 ± 0.53	−0.2 to 0	.0052	0.19
Posttreatment	0.2 ± 0.5	4.1 ± 0.82	3.9–4.2	<.001	4.88	4.2 ± 0.91	−0.1 ± 0.53	−0.2 to 0	.0052	0.19

MPQ = McGill pain questionnaire; SD = standard deviation; SRM = standardized response mean; TBF = turmeric-boswellia formulation.

^*

Wilcoxon signed-rank test.

^†

SRM = mean change/SD of the change.